Galectin Therapeutics (NASDAQ:GALT - Get Free Report) issued its earnings results on Monday. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03), Zacks reports.
Galectin Therapeutics Price Performance
Shares of NASDAQ GALT traded down $0.04 during trading on Friday, hitting $1.24. The stock had a trading volume of 205,139 shares, compared to its average volume of 325,738. The firm has a fifty day moving average of $1.46 and a two-hundred day moving average of $1.95. Galectin Therapeutics has a 12 month low of $0.73 and a 12 month high of $4.27. The company has a market capitalization of $77.89 million, a PE ratio of -1.71 and a beta of 0.69.
Analysts Set New Price Targets
Several equities research analysts have recently commented on GALT shares. HC Wainwright reissued a "neutral" rating on shares of Galectin Therapeutics in a research report on Wednesday. StockNews.com downgraded Galectin Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, December 30th.
Check Out Our Latest Stock Analysis on Galectin Therapeutics
Institutional Investors Weigh In On Galectin Therapeutics
A hedge fund recently raised its stake in Galectin Therapeutics stock. Bank of America Corp DE lifted its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 38,358 shares of the company's stock after acquiring an additional 19,316 shares during the quarter. Bank of America Corp DE owned 0.06% of Galectin Therapeutics worth $49,000 at the end of the most recent quarter. 11.68% of the stock is owned by hedge funds and other institutional investors.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Read More
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
